Siegel RL, Wagle NS, Cercek A, Smith RA. Jemal A 2023 colorectal cancer statistics. CA: Cancer J Clin. 2023;73:233–54.

PubMed  Google Scholar 

Benson AB, Venook AP, Al-Hawary MM, et al. ColonCancer, version 2.2021, NCCN Clinical Practice Guidelines in oncology. J Natl Compr Canc Netw. 2021;19:329–35.

Article  PubMed  Google Scholar 

Alzahrani S, Al Doghaither H, Al-ghafari A, Pushparaj P. 5-fluorouracil and capecitabine therapies for the treatment of colorectal cancer (review). Oncol Rep. 2023. https://doi.org/10.3892/or.2023.8612.

Article  PubMed  Google Scholar 

He X, Lan H, Jin K, Liu F. Can immunotherapy reinforce chemotherapy efficacy? A new perspective on colorectal cancer treatment. Front Immunol. 2023. https://doi.org/10.3389/fimmu.2023.1237764.

Article  PubMed  PubMed Central  Google Scholar 

Georgilis E, Gavriatopoulou M, Tsilimigras DI, Malandrakis P, Theodosopoulos T, Ntanasis-Stathopoulos I. Optimizing adjuvant therapy after surgery for colorectal cancer liver metastases: a systematic review. J Clin Med. 2023;20(12):2401.

Article  Google Scholar 

Deng Y, Li X. Fruquintinib and its use in the treatment of metastatic colorectal cancer. Future Oncol. 2019;15:2571–6.

Article  CAS  PubMed  Google Scholar 

Xu X, Yu Y, Liu M, Liang L, Liu T. Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review. Transl Cancer Res. 2022;11:276–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang RT, Zhao Y, Wang AL, Wang YT, Yin ZP, Chen K. Efficacy and safety of regorafenib monotherapy among patients with previously treated metastatic colorectal cancer in a chinese population: a real-world exploratory study. Int J Gen Med. 2021;7(14):5363–73.

Article  Google Scholar 

Grothey A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;26(381):303–12.

Article  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021. https://doi.org/10.1136/bmj.n71.

Article  PubMed  PubMed Central  Google Scholar 

Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:1–8.

Google Scholar 

Tantry TP, Karanth H, Shetty PK, et al. Self-learning software tools for data analysis in meta-analysis. Korean J Anesthesiol. 2021;74:459–61.

Article  PubMed  PubMed Central  Google Scholar 

Dasari A, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023;1(402):41–53.

Article  Google Scholar 

Li J, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. JAMA. 2018;26(319):2486–96.

Article  Google Scholar 

Xu RH, et al. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. 2017;19(10):22.

Article  Google Scholar 

Stucchi E, Bartolini M, Airoldi M, Fazio R, Daprà V, Mondello G, et al. Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence? Expert Opin Pharmacother. 2024;3(25):371–82.

Article  Google Scholar 

Zhang Y, Zou JY, Wang Z, Wang Y. Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer. Cancer Manag Res. 2019;16(11):7787–803.

Article  Google Scholar 

Zheng RS, Chen R, Han BF, et al. Cancer incidence and mortality in China, 2022. Zhonghua Zhong Liu Za Zhi. 2024;46:221–3.

CAS  PubMed  Google Scholar 

Gangireddy A, Reddy VG, Talla S. Gender disparities in the incidence of colorectal cancer in the era of screening colonoscopy: 176. Am J Gastroenterol. 2018. https://doi.org/10.14309/00000434-201810001-00176.

Article  Google Scholar 

Meng L, Thapa R, Delgado MG, et al. Association of age with treatment-related adverse events and survival in patients with metastatic colorectal cancer. JAMA Netw Open. 2023;6: e2320035.

Article  PubMed  PubMed Central  Google Scholar 

Wang Y, et al. Fruquintinib in metastatic colorectal cancer: a multicenter real-world analysis on efficacy, safety, and predictive and prognostic factors. J Gastrointest Oncol. 2024;15:1519–33.

Article  PubMed  PubMed Central  Google Scholar 

Zhang Q, Wang Q, Wang X, Li J, Shen L, Peng Z. Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials? Int J Colorectal Dis. 2020;35:295–306.

Article  PubMed  Google Scholar 

Zou J, et al. A retrospective study of trifluridine/tipiracil with fruquintinib in patients with chemorefractory metastatic colorectal cancer. J Clin Med. 2023;21(13):57.

Article  Google Scholar 

Lu S, Chang J, Liu X, et al. Randomized, double-blind, placebo-controlled, multicenter phase II study of fruquintinib after two prior chemotherapy regimens in Chinese patients with advanced nonsquamous Non-Small-Cell lung cancer. J Clin Oncol. 2018;36:1207–17.

Article  CAS  PubMed  Google Scholar 

Lu S, Chen G, Sun Y, Sun S, Chang J, Yao Y, et al. Ma14.05 a randomized phase III trial of Fruquintinib versus placebo in patients with advanced non-small cell lung cancer (FALUCA). J Thorac Oncol. 2019. https://doi.org/10.1016/j.jtho.2019.08.613.

Article  PubMed  PubMed Central  Google Scholar 

Wang F, et al. Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial. Nat Med. 2024;30:2189–98.

Article  CAS  PubMed  Google Scholar 

Jing Z, Rui Z, Binglan Z. A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis. J Cancer Res Clin Oncol. 2019;145:2313–23.

Article  PubMed  Google Scholar 

Li J, et al. Safety profile and adverse events of special interest for fruquintinib in Chinese patients with previously treated metastatic colorectal cancer: analysis of the phase 3 FRESCO trial. Adv Ther. 2020;37:4585–98.

Article  CAS  PubMed  Google Scholar